{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-106461","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.379080+00:00","generated_at":"2026-05-30T19:21:36.984948+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Apitegromab meets Phase 3 primary endpoint in SMA; Scholar Rock plans BLA/MAA filing Q1 2025","bullets":["Primary endpoint met: apitegromab improved HFMSE vs placebo (mean diff 1.8 points, p=0.0192) in patients ages 2-12.","30.4% of apitegromab patients had >3 point HFMSE improvement vs 12.5% on placebo.","Benefit observed from first time point at 8 weeks, sustained to 52 weeks.","Safety profile consistent with prior trials; no SAEs related to apitegromab.","Company plans to submit BLA to FDA and MAA to EMA in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-106461","json":"https://secwatch.observer/filing/0001104659-24-106461.json","markdown":"https://secwatch.observer/filing/0001104659-24-106461.md","text":"https://secwatch.observer/filing/0001104659-24-106461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000110465924106461/0001104659-24-106461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000110465924106461/tm2425688d7_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:21:36.984948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}